A case of immune myositis and peripheral neuropathy induced by immune checkpoint inhibitor

Published on May. 06, 2023Total Views: 1371 times Total Downloads: 504 times Download Mobile

Author: Tian-Zi XU Teng-Fei WANG Yi-Xin LIU  Yong-Chang WEI

Affiliation: Department of Gastrointestinal Tumors Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Wuhan 430071, China

Keywords: Immune checkpoint inhibitors Immune myositis Peripheral neuropathy Perihilar cholangiocarcinoma

DOI: 10.12173/j.issn.1004-4337.202303118

Reference: Xu TZ, Wang TF, Liu YX, Wei YC. A case of immune myositis and peripheral neuropathy induced by immune checkpoint inhibitor[J]. Journal of Mathematical Medicine, 2023, 36(4): 316-320. DOI: 10.12173/j.issn.1004-5511.202303118[Article in Chinese]  Copied

Abstract
Full-text
References

Abstract

A retrospective analysis of the diagnosis and treatment of a patients with advanced perihilar cholangiocarcinoma with immunodeficiency and peripheral neuropathy induced by terbutal-ine was conducted, and clinical features and principles of diagnosis and treatment were summarized in combination with relevant literature on immune checkpoint inhibitors. In the application of antitumor immunotherapy, clinicians should closely monitor relevant indicators of the patients and be alert to the occurrence of immune-related adverse reactions so that early diagnosis and intervention can be made. The discontinuation of immunotherapy and the use of corticosteroids and/or immunosuppressant therapy are critical to the prognosis of patients with immune-related adverse events (irAEs).

Full-text

Please download the PDF version to read the full text: download

References

1.Khan AS, Dageforde LA. Cholangiocarcinoma[J]. Surg Clin North Am, 2019, 99(2): 315-335. DOI: 10.1016/j.suc. 2018.12.004.

2.Aloia TA. Precision hilar cholangiocarcinoma surgery[J]. Ann Surg Oncol, 2018, 25(5): 1103-1104. DOI: 10.1245/s10434-018-6416-7.

3.Mansour JC, Aloia TA, Crane CH, et al. Hilar cholangiocarcinoma: expert consensus statement[J]. HPB (Oxford), 2015, 17(8): 691-699. DOI: 10.1111/hpb.12450.

4.Nagino M, Ebata T, Yokoyama Y, et al. Evolution of surgical treatment for perihilar cholangiocarcinoma: a single-center 34-year review of 574 consecutive resections[J]. Ann Surg, 2013, 258(1): 129-140. DOI: 10.1097/SLA.0b013e3182708b57.

5.Kadota H, Gono T, Shirai Y, et al. Immune checkpoint inhibitor-induced myositis: a case report and literature review[J]. Curr Rheumatol Rep, 2019, 21(4): 10. DOI: 10.1007/s11926-019-0811-3.

6.Kostine M, Finckh A, Bingham CO, et al. EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors[J]. Ann Rheum Dis, 2021, 80(1): 36-48. DOI: 10.1136/annrheumdis-2020-217139.

7.张正凤, 杨磊, 王大榛, 等. 局部进展期或晚期胆道恶性肿瘤治疗的现状及进展[J]. 中国肿瘤, 2022, 31(7): 569-577. [Zhang ZF, Yang L, Wang DZ, et al. Current status and progress in the treatment of locally advanced or advanced biliary tract cancer[J]. China Cancer, 2022, 31(7): 569-577.] DOI: 10.11735/j.issn.1004-0242.2022.07.A009.

8.Murciano-Goroff YR, Warner AB, Wolchok JD. The future of cancer immunotherapy: microenviron-ment-targeting combinations[J]. Cell Res, 2020, 30(6): 507-519. DOI: 10.1038/s41422-020-0337-2.

9.Wang DY, Salem JE, Cohen JV, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis[J]. JAMA Oncol, 2018, 4(12): 1721-1728. DOI: 10.1001/jamaoncol.2018.3923.

10.Psimaras D, Velasco R, Birzu C, et al. Immune checkpoint inhibitors-induced neuromuscular toxicity: from pathogenesis to treatment[J]. J Peripher Nerv Syst, 2019, 24 Suppl 2: S74-S85. DOI: 10.1111/jns.12339.

11.Zhao Z, Zhang C, Zhou L, et al. Immune checkpoint inhibitors and neurotoxicity[J]. Curr Neuropharmacol, 2021, 19(8): 1246-1263. DOI: 10.2174/1570159X19666201230151224.

12.Chen X, Haggiagi A, Tzatha E, et al. Electrophysiological findings in immune checkpoint inhibitor-related peripheral neuropathy[J]. Clin Neurophysiol, 2019, 130(8): 1440-1445. DOI: 10.1016/j.clinph.2019.03.035.

13.钟庆玲, 曾莉, 谈颂. 免疫检查点抑制剂相关神经肌病[J]. 华西医学, 2020, 35(6): 734-737. [Zhong QL, Zeng L, Tan S. Immune checkpoint inhibitors-related neuromyopathy[J]. West China Medical Journal, 2020, 35(6): 734-737.] DOI: 10.7507/1002-0179.202003528.

14.Bonetto G, Di Scala C. Importance of lipids for nervous system integrity: cooperation between gan-gliosides and sulfatides in myelin stability[J]. J Neurosci, 2019, 39(32): 6218-6220. DOI: 10.1523/JNEUROSCI.0377-19.2019.

15.Sloan G, Selvarajah D, Tesfaye S. Pathogenesis, diagnosis and clinical management of diabetic sen-sorimotor peripheral neuropathy[J]. Nat Rev Endocrinol, 2021, 17(7): 400-420. DOI: 10.1038/s41574-021-00496-z.

16.Kokotis P, Schmelz M, Kostouros E, et al. Oxaliplatin-induced neuropathy: a long-term clinical and neurophysiologic follow-up study[J]. Clin Colorectal Cancer, 2016, 15(3): e133-e140. DOI: 10.1016/j.clcc. 2016.02.009.

17.Allenbach Y, Anquetil C, Manouchehri A, et al. Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities[J]. Autoimmun Rev, 2020, 19(8): 102586. DOI: 10.1016/j.autrev.2020.102586.

18.Poto R, Troiani T, Criscuolo G, et al. Holistic approach to immune checkpoint inhibitor-related adverse events[J]. Front Immunol, 2022, 13: 804597. DOI: 10.3389/fimmu. 2022.804597.

19.Kadokawa Y, Takagi M, Yoshida T, et al. Efficacy and safety of infliximab for steroid-resistant im-mune-related adverse events: a retrospective study[J]. Mol Clin Oncol, 2021, 14(4): 65. DOI: 10.3892/mco.2021.2227.